<DOC>
	<DOCNO>NCT00799721</DOCNO>
	<brief_summary>VLBW infant risk develop retinopathy prematurity ( ROP ) . In first phase ROP down-regulation retinal VEGF-expression postnatal relative hyperoxia , follow upregulation VEGF mediate retinal hypoxia , lead pathologic vessel formation . VEGF act bind specific receptor FLT-1 , soluble form sFLT-1 specific antagonist VEGF action . Erythropoietin , give VLBW infant prevent anemia , may stimulate VEGF-production neuronal cell . Currently , data publish VEGF urine-levels VLBW infant know , urine VEGF-levels may serve non-invasive marker ROP-risk . Further shall investigate , erythropoietin-therapy increase urine VEGF-levels correlation ROP-development .</brief_summary>
	<brief_title>Urine VEGF Levels Very Low Birth Weight ( VLBW ) Infants</brief_title>
	<detailed_description />
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>gestational age &lt; 32 week birth weight &lt; 1500g absent write consent parent connatal eye malformation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>32 Weeks</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>ROP</keyword>
	<keyword>VLBW</keyword>
	<keyword>Epo</keyword>
	<keyword>IUGR</keyword>
	<keyword>VEGF</keyword>
	<keyword>sFLT-1</keyword>
	<keyword>low birth weight infant</keyword>
	<keyword>retinopathy prematurity</keyword>
	<keyword>erythropoietin therapy risk ROP</keyword>
</DOC>